Strategic Analysis of the Global Pharmaceutical Contract Manufacturing Industry

The global pharmaceutical contract manufacturing/contract research market is anticipated to reach USD 238.3 billion by 2025, according to a new report by Grand View Research, Inc. Impact on the volume of capacity that is required for production due to of increasing expression levels is anticipated to influence outsourcing industry. Increased cell densities as well as increase in expression of each cell has led to the steady decline in the volume requirement. The aforementioned fact provides the client with choices for in selection from several CMOs, which was not the fact earlier. 

View summary of this report, Click Here 

The focus of large pharmaceutical companies to strategically engage with a small number of preferred providers is a meaningful departure from the procurement-based outsourcing. This was one of the many approaches that the service industry had become accustomed to.

Expanding market for biosimilars and biobetters is anticipated to pronounce the demand for contract development and manufacturing support. Service providers that hold the potential of providing cost as well as quality advantages are set to make inroads and grow at tremendous pace in the forecast period.

However, as drug manufacturers are increasing the investments with respect to production capabilities. This may limit the potential growth of contract manufacturing services to traditional customers thereby hampering industrial growth.

Further Key Findings from the Report Suggest:

• Contract manufacturing services estimated to dominate the market over research services
• These services are segmented on the basis of development of different forms of formulations. Active Pharmaceutical Ingredient (API) / Bulk drugs registered the largest share of revenue.
• Pharmaceutical companies prefer the outsourcing services for API research and manufacture
• Factors supportive for this trend includes reduction in the cost of production of APIs
• Active molecules from small companies are always acquired by the big pharmaceutical companies
• The prominent entities focus on marketing rather than core competencies of production of API in order to maintain presence
• Finished dose formulations are expected to register the fastest growth in the coming years
• Contract research services for oncology dominated the market and are anticipated to maintain the dominance in the coming years
• CMOs/CDMOs with the ability to establish facilities in emerging countries are expected to drive growth
• Companies can position themselves for strong growth, given that demand is expected to expand rapidly in the coming years
• The major countries include Brazil. Russia, India, and China as the contract service sector is in its infancy in these regions
• Key players contributing in this market are AbbVie Contract Manufacturing, Catalent, Grifols International, S.A., Baxter BioPharma Solutions, Boehringer Ingelheim Biopharmaceuticals Gmbh, Dalton Pharma Services, and Patheon.
• Companies are engaged in lifecycle management of small-molecule drugs through the development of modified generics with uniquely enhanced properties

Click Here For Continue Reading : https://goo.gl/cBe2oX

Click Here For Sample Report : https://goo.gl/mYk41c

Air Ambulance Services Market Global Analysis, Opportunities and Forecast To 2025

The global air ambulance services market is expected to reach USD 8.2 billion by 2025, according to a new report by Grand View Research, Inc. Increasing incidents of life-threatening diseases, such as cardiovascular disorders, that require emergency medical response support the lucrative growth of the market over the forecast period. In addition, increasing awareness about air medical transport services also spurs growth of this market. Furthermore, Availability of reimbursement in developed countries, such as the U.S., helps people avail these services despite the high cost.

                                     View summary of this report, Click Here

Improving global economy led to increased spending, which resulted in increased spending on healthcare. The per capita healthcare expenditure has increased exponentially over the last couple of decades. This per capita health expenditure increased by about 55.0% from 1996 to 2014 as published by The World Bank Group. As a result, the demand for these services has been increasing over the forecast period.

This industry is capital intensive, yet there exhibits constant entry of new players, which has helped maintain the supply-demand balance in fierce market place. For instance, in 2012 there were more than 300 players operating in this space with around 1,300 aircrafts, and this number is likely to increase over the forecast period.

Further key findings from the study suggest:

• Rotary-wing air ambulance services, which include helicopter-based services, held a lucrative share in 2015. Easy usability of helicopters and low cost of these services governed their dominance.
• Fixed-wing services include specialized aircrafts having medical facilities and dedicated crew. Rising medical tourism and operability of these aircrafts in adverse weather conditions are few reasons for their increased demand.
• Hospital based service dominated service model segment in 2015 and also anticipated to grow at healthy rate over the forecasts period.
• North America dominated the global air ambulance market in 2016 due to established infrastructure for air medical transport.
• Asia Pacific is anticipated to gain lucrative share over the forecast period. Strengthening economy, especially of countries such as India and China, investments from global conglomerates, and improving business opportunities are likely to provide growth avenues for players.
• Some of the key players in this vertical include AMR; PHI Air Medical; Scandinavian Air Ambulance; IAS Medical; Express AirMed Transport; Native American Air Ambulance; Lifeguard Air Ambulance, REVA Air Ambulance and Acadian.
• Strategic initiatives undertaken by these players include collaboration, service portfolio expansion, and partnerships with business firms & sports and entertainment events.

For Sample Request Send Us Here : https://goo.gl/yecS1f

Global Breast Imaging Devices Market Trends, Designs, Growth Factors & Applications

The global breast imaging market is expected to reach USD 7.3 billion by 2024, according to a new report by Grand View Research, Inc. The increasing incidences of breast cancer coupled with the continual product improvements being launched and the numerous R&D innovation initiatives being undertaken in the field of cancer are expected to collectively boost the growth of the market over the forecast period.

In 2012, the WHO estimated that around 53.0% of the global women population (1.8 billion women) is anticipated to suffer from breast cancer over their lifespan. This alarmingly rising rate is expected to be the preliminary driver for this market over the forecast period.

The rising base of the geriatric population is another high impact rendering driver of the breast imaging market. A study by the NCBI (National Center for Biotechnology Information) stated that the incidence of breast cancer is higher in patients above the age group of 45.

Increasing expenditure on R&D coupled with government funding are the other vital factors expected to trigger market growth over the forecast period. In 2013, the National Institute of Health, in the U.S. provided a grant amounting to USD 5.6 billion to conduct research on breast cancer. Digital mammography is one of the technologies gaining popularity as compared to other technologies, which is expected to positively reinforce this market’s growth.

However, the high cost of the existing imaging systems coupled with the stringent regulatory policies governing the approval of new products and marketing are predicted to slowdown growth.

View summary of this report, Click Here 

Further key findings from the study suggest:

• The 3D tomosynthesis segment is identified as the fastest growing segment. This technology offers enhanced efficiency and higher diagnostic accuracy in comparison to other available technologies, which is expected to aid market growth.
• North America is likely to dominate throughout the forecast period with a revenue share of over 30.0% by 2024.Government initiatives including the precision medicine initiative, started by President Obama in 2015, promotes the development of personalized medicine, which is anticipated to foster market growth.
• Asia Pacific is anticipated to grow at the fastest rate of12.0% over the forecast period. The Increasing number of investments in the healthcare sector coupled with the rising awareness of breast cancer and other associated conditions is anticipated to propel the market growth in this region.
• Some major players of the market are Siemens Healthcare, GE Healthcare, Dilon Technologies, Inc., Hologic, Inc., Gamma Medica, Inc., Fujifilm Holdings Corporation, SonoCine, Inc., Philips Healthcare, Toshiba Corporation, and Aurora Imaging Technology, Inc.
• In order to gain a competitive advantage in the market, the key industry players are adhering to mergers, acquisitions and collaborative agreements. For instance, in January 2016, Gamma Medica, Inc. entered into a contract with Alpha Imaging Technology Corp. for the commercialization of its new product, Luma GEM.

Click Here For Continue Reading : https://goo.gl/RHH9HZ

Sample Request of this Report : sales@grandviewresearch.com

Complementary & alternative medicine market is expected to generate a revenue of USD 196.87 billion by 2025

Factors such as the increase in adoption of alternative medicine by people combined with the government initiatives of a number of key countries to enhance reach is expected to help in expansion revenue generation avenues.

Complementary and alternative forms of therapy are used in the treatment of chronic ailments, long-term pain among others and are also used for additional vitamins and other dietary supplementation of regular diet. Moreover, with considerable increase in the costs of conventional medicine and inclination towards body wellness rather than pharmaceutical cure is likely to boost the market over the forecast period. 

As of early 2016, approximately two thirds of the population in most of the developed and developing countries have reported using one or the other form of alternative or complementary form of medicine. There are certain countries that are moving towards the legalization of some alternative medicine therapies that are being backed with approved clinical data.

                                   View summary of this report, Click Here 

Further key findings from the report suggest:

• The market is driven by high adoption rates of herbal dietary supplements other wellness therapies like yoga, acupuncture
• Usage of botanicals has become the most prominent form of alternative medicine as the segment was observed to account for generation of the largest share of revenue
• Europe and the Asia Pacific regions emerge as clear hotspots for these forms of therapies and combine to generate the major share of market revenue
• Developing regions such as Latin America and Middle East Asia are set to witness considerable growth in demand over the forecast period driven by the expensive nature of conventional medicine and lack thereof is certain countries
• Some of the key players and wellness institutes active in the market are Pacific Nutritional Inc, Herb Pharm, Herbal Hills, Helio USA Inc, Deepure Plus, Nordic Naturals, Pure encapsulations, Inc., and other wellness institutes like Iyengar Yoga Institute, John Schumacher’s Unity Woods Yoga Center, Yoga Tree, The Healing Company and Quantum Touch Inc.

For More Access Click Here:  https://goo.gl/eih9RV

Rising prevalence of chronic diseases such as cardiac and neurological disorders is expected to be the major factor driving the electroceuticals/bioelectric medicine market growth

The global electroceuticals/bioelectric medicine market is expected to reach USD 35.5 billion by 2025, according to a new report by Grand View Research, Inc. Rising geriatric population is the major factor that is expected to propel growth during the forecast period. Aging population is prone to various diseases such as cardiac arrhythmias, Parkinson's disease, Alzheimer's disease, epilepsy, and depression. There are various advanced electroceuticals including implantable cardioverter defibrillators, cochlear implants, cardiac pacemakers, and spinal cord stimulators, which can be used for the treatment of these conditions. 

Increasing investment in the development of advanced bioelectric medicine is another major factor supporting the growth of the electroceuticals market. For instance, in FY 2016, Medtronic, a leading bioelectric medicine manufacturer, invested around USD 2,224 million in R&D for development of advanced products. Technological advancements in these products propel their adoption in treatment of chronic diseases such as cardiac arrhythmias and Parkinson's disease. The technological advanced electroceuticals provide high reliability and efficiency during treatment.

View summary of this report, Click Here 

Further Key Findings From The Report Suggest:

• Implantable cardioverter defibrillators segment was the largest revenue-generating segment of the electroceuticals market in 2016 owing to large application of these products for the treatment of arrhythmia
• The implantable electroceuticals devices segment accounted for the largest revenue share in the bioelectric medicine market in 2016 owing to technological advancements
• In the application segment, the arrhythmia segment accounted for the largest share in 2016 and is expected to maintain its dominance throughout forecast period
• The hospitals dominated the electroceuticals market in terms of revenue in 2016 due to the escalating number of electroceutical devices implant procedures in hospitals
• The North America bioelectric medicine market is the leading regional sector and accounted for the largest revenue share in 2016 mainly due to the existence of large number of medical devices companies in this region
• The Asia Pacific region is expected to grow at a highest growth rate during the study period. The developing healthcare infrastructure and rising healthcare awareness in the Asian countries such as China and India is a major factor contributing to the growth in this region
• Some of the major players include Medtronic; St. Jude Medical; Boston Scientific Corporation; Cochlear Ltd.; Sonova; LivaNova PLC; Biotronik; Nevro Corp.; SECOND SIGHT; and electroCore LLC. 

Click Here For Access Full Report : https://goo.gl/yLgNPc

Click Here For Request Sample Report :https://goo.gl/vSuZpy

Reasons Why You Should Invest In Oncology Based In-vivo CRO Market

The global oncology based in-vivo CRO market is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc. The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.

Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.

Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide.

View summary of this report, Click Here 

Further key findings from the study suggest:

• Based on indication, solid tumors are expected to dominate the market as of 2016. Furthermore, it is anticipated to grow at the fastest CAGR owing to the factors such as growing incidence rate, augmenting research for tumors in organs such as breast, and liver, and technological advancement offered by key industry players.
• Solid tumors are analyzed by means of models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The PDX models are expected to witness lucrative growth over the forecast period and capture over 40.0% of the market share by 2025.
• Geographic expansion into Asia Pacific countries by well-established players is anticipated to promote the fastest growth for the region. India is one the most lucrative country owing to presence of service tax exemption and venture capital based funding for CROs.
• Few of the industry players for the oncology based in-vivo CRO market are The Jackson Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC, Wuxi AppTec, and ICON Plc.
• A common trend observed is the rising partnerships among CROs to offer bundle packages of services to sponsors. For instance, In May 2017, CRL International, Inc. announced their partnership with OcellO, established in Netherlands. According to this partnership, CRL would be utilizing the latter’s PDX model capabilities in order to expand their oncology based drug discovery service portfolio.

For Access Full Report Click Here :  https://goo.gl/xDBbEf

Increasing demand for therapeutic drugs including pharmaceuticals, biopharmaceuticals, and biologics is the major factor to grow pyrogen testing market

The global pyrogen testing market is expected to reach a value of USD 1.9 billion by 2025, according to a new report by Grand View Research, Inc. Increasing demand for therapeutic drugs including pharmaceuticals, biopharmaceuticals, and biologics is the major factor that propels growth of the market during forecast period. Pyrogen is a toxic molecular substance that causes fever if induced in animal or human body. Pyrogen testing is used by pharmaceutical, biopharmaceuticals, biotechnology, and medical devices companies to confirm the absence of pyrogen. Thus, the companies use various methods such as LAL, in vitro pyrogen, and rabbit test to ensure the quality of products.

Increasing prevalence of chronic diseases, is another foremost factor supporting the growth of the pyrogen testing market. The prevalence of chronic diseases is very high in developed countries and is growing at high pace in developing countries including China and India. Different factors such as unhealthy diet, smoking, alcohol consumption, and lack of exercise leads to occurrence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases.  Hence, there is a growing demand for therapeutic drugs and medical devices for the treatment of such diseases, which in turn is projected to fuel the demand for pyrogen testing to ensure the quality of products including drugs and devices.

View summary of this report, Click Here

Further key findings from the study suggest:

• Consumables was the largest revenue grossing segment of the pyrogen testing market in 2016, owing to the large application of pyrogen testing kits and reagents along with its repetitive purchase
• Instruments segment accounted for the remarkable share in the market in 2016 and is also expected to showcase significant growth during forecast period, owing to rising demand for pharmaceutical, biologics, and medical devices for treatment and diagnosis
• The pharmaceutical and biotechnology companies segment dominated the pyrogen testing market in terms of revenue in 2016, due to the large production of therapeutic drugs and growing investment in R&D by companies for drug development
• North America is the leading regional market and accounted for the largest revenue share in 2016 primarily due to the existence of large number of healthcare companies including pharmaceuticals and medical devices in this region
• The Asia Pacific region is anticipated to be the fastest growing market during the study period. The growing prevalence rate of chronic diseases in the Asian countries including India and China, is a major factor contributing to the expansion of market in this region.
• Some major players serving this vertical include Charles River Laboratories, Inc.; Ellab A/S; Merck KGaA; GenScript; Hyglos GmbH; Lonza; Thermo Fisher Scientific, Inc.; Associates of Cape Cod, Inc.; and Pyrostar

Click Here For Access Full Report : https://goo.gl/VhcZPt